These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16241992)

  • 1. Breast pathology practice: most common problems in a consultation service.
    Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO
    Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
    Bofin AM; Lydersen S; Hagmar BM
    Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillary lesions of the breast: selected diagnostic and management issues.
    Collins LC; Schnitt SJ
    Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interobserver reproducibility in the pathologic diagnosis of borderline ductal proliferative breast diseases].
    Wei B; Bu H; Zhu CR; Guo LX; Chen HJ; Zhao C; Zhang P; Chen DY; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):849-53. PubMed ID: 15573772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary lesions of the breast.
    Ibarra JA
    Breast J; 2006; 12(3):237-51. PubMed ID: 16684322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
    MacGrogan G
    Ann Pathol; 2009 Jun; 29(3):188-93. PubMed ID: 19619824
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
    Lee AH
    J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Moriya T
    J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study.
    Raju U; Vertes D
    Hum Pathol; 1996 Nov; 27(11):1231-8. PubMed ID: 8912836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artefactual Epithelial Displacement in a Papilloma with Extensive Usual Duct Hyperplasia Mimics a Solid Papillary Carcinoma with Invasive Growth.
    François A; Galant C; Berlière M; Van Bockstal MR
    Int J Surg Pathol; 2021 Jun; 29(4):395-399. PubMed ID: 33736513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
    MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
    Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of papillary lesions at percutaneous breast biopsy.
    Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A
    Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant breast lesions that may mimic benign tumors.
    Weidner N
    Semin Diagn Pathol; 1995 Feb; 12(1):2-13. PubMed ID: 7770672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ; Guinebretière JM; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
    Pinder SE; Ellis IO
    Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ of the breast.
    Masood S; Sim SJ; Lu L
    Cancer Detect Prev; 1992; 16(4):225-35. PubMed ID: 1281040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borderline breast lesions: diagnostic challenges and clinical implications.
    Masood S; Rosa M
    Adv Anat Pathol; 2011 May; 18(3):190-8. PubMed ID: 21490436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
    Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
    Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.